

PACCARB Task from the Secretary HHS

What is the best way to incentivize the development of therapeutics (including alternatives to antibiotics), rapid diagnostics, and vaccines for both humans and animals while maximizing the return on investment, and still encouraging appropriate stewardship, and access to products?



PACCARB

Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria

Questions Asked of Presenters

- What incentives have been tried and what has worked?
- Are there opportunities for early successes (“low hanging” fruit)?
- Which approaches are ‘realistic’ and can help:
 - Maximize return on investment for companies and have the greatest impact on USG resources;
 - Encourage stewardship; and
 - Maintain access to the product.



PACCARB

Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria

Today's Sessions on Incentives for Antibiotics, Vaccines, and Diagnostics

- USG Experience and Economic Incentives 101 (human and animal)
- International Experience: AMR Review (phone) and the DRIVE-AB Approach
- Industry Experience: Health for Animals (phone), BIO, and bioMerieux



PACCARB

Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria